干细胞衍生的配子:期待其临床应用时的期望。

IF 6 1区 医学 Q1 OBSTETRICS & GYNECOLOGY
Ilse J de Bruin,Merel M Spaander,Simone Harmsen,Rosanne Edelenbosch,M Corrette Ploem,Nina Dartée,Madalena Cardoso Vaz Santos,Mathangi Lakshmipathi,Callista L Mulder,Ans M M van Pelt,Willy M Baarends,Susana M Chuva de Sousa Lopes,Guido M W R de Wert,Seppe Segers,Geert Hamer,Ana M Pereira Daoud
{"title":"干细胞衍生的配子:期待其临床应用时的期望。","authors":"Ilse J de Bruin,Merel M Spaander,Simone Harmsen,Rosanne Edelenbosch,M Corrette Ploem,Nina Dartée,Madalena Cardoso Vaz Santos,Mathangi Lakshmipathi,Callista L Mulder,Ans M M van Pelt,Willy M Baarends,Susana M Chuva de Sousa Lopes,Guido M W R de Wert,Seppe Segers,Geert Hamer,Ana M Pereira Daoud","doi":"10.1093/humrep/deaf123","DOIUrl":null,"url":null,"abstract":"Stem cell-derived (SCD)-gametes derived from induced or autologous (i.e. patient-specific) cells may help mitigate human fertility problems caused by physiological or social factors in the (near) future. While this technology is still in its infancy, recent advancements with SCD-gametes generated from mouse pluripotent stem cells have led some researchers to expect-and investors to anticipate-the clinical introduction of human gametes derived from induced pluripotent stem cells (iPSCD-gametes) within two decades. However, it remains to be investigated how realistic these expectations are, and how they would balance against careful consideration of technical, ethical, legal, and societal aspects, including-but not limited to-safety and effectiveness. This mini-review aims to encourage that investigation by providing a brief overview of the state-of-the-art and highlighting the breadth of issues involved in the potential clinical introduction of human iPSCD-gametes. These issues emerge before (Stage 1), during (Stage 2), and after (Stage 3) clinical trials, and are discussed in that order. Issues discussed in the context of Stage 1 suggest that gathering the evidence required to preclinically assess the safety of human iPSCD-gametes will be time-consuming and require parallel experiments with sensitive research materials. Issues discussed in the context of Stage 2 suggest that it might take several years for human iPSCD-gametes to transition through distinct clinical trial phases, and that inevitable (and unforeseeable) variations in the quality of human iPSCD-gametes are likely to further slow this down. Finally, issues discussed in the context of Stage 3 suggest that offering human iPSCD-gametes clinically will require addressing questions of accountability and monitoring, some of which might be difficult to formalize by law. Combined, these findings suggest that a responsible clinical introduction of human iPSCD-gametes may take considerably longer than expected, underscoring the importance of transdisciplinary collaborations with a broad range of stakeholders to make well-informed and well-considered choices about their development and application.","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":"50 1","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Stem cell-derived gametes: what to expect when expecting their clinical introduction.\",\"authors\":\"Ilse J de Bruin,Merel M Spaander,Simone Harmsen,Rosanne Edelenbosch,M Corrette Ploem,Nina Dartée,Madalena Cardoso Vaz Santos,Mathangi Lakshmipathi,Callista L Mulder,Ans M M van Pelt,Willy M Baarends,Susana M Chuva de Sousa Lopes,Guido M W R de Wert,Seppe Segers,Geert Hamer,Ana M Pereira Daoud\",\"doi\":\"10.1093/humrep/deaf123\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Stem cell-derived (SCD)-gametes derived from induced or autologous (i.e. patient-specific) cells may help mitigate human fertility problems caused by physiological or social factors in the (near) future. While this technology is still in its infancy, recent advancements with SCD-gametes generated from mouse pluripotent stem cells have led some researchers to expect-and investors to anticipate-the clinical introduction of human gametes derived from induced pluripotent stem cells (iPSCD-gametes) within two decades. However, it remains to be investigated how realistic these expectations are, and how they would balance against careful consideration of technical, ethical, legal, and societal aspects, including-but not limited to-safety and effectiveness. This mini-review aims to encourage that investigation by providing a brief overview of the state-of-the-art and highlighting the breadth of issues involved in the potential clinical introduction of human iPSCD-gametes. These issues emerge before (Stage 1), during (Stage 2), and after (Stage 3) clinical trials, and are discussed in that order. Issues discussed in the context of Stage 1 suggest that gathering the evidence required to preclinically assess the safety of human iPSCD-gametes will be time-consuming and require parallel experiments with sensitive research materials. Issues discussed in the context of Stage 2 suggest that it might take several years for human iPSCD-gametes to transition through distinct clinical trial phases, and that inevitable (and unforeseeable) variations in the quality of human iPSCD-gametes are likely to further slow this down. Finally, issues discussed in the context of Stage 3 suggest that offering human iPSCD-gametes clinically will require addressing questions of accountability and monitoring, some of which might be difficult to formalize by law. Combined, these findings suggest that a responsible clinical introduction of human iPSCD-gametes may take considerably longer than expected, underscoring the importance of transdisciplinary collaborations with a broad range of stakeholders to make well-informed and well-considered choices about their development and application.\",\"PeriodicalId\":13003,\"journal\":{\"name\":\"Human reproduction\",\"volume\":\"50 1\",\"pages\":\"\"},\"PeriodicalIF\":6.0000,\"publicationDate\":\"2025-07-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human reproduction\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/humrep/deaf123\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human reproduction","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/humrep/deaf123","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

干细胞衍生(SCD)-配子来自诱导或自体(即患者特异性)细胞可能有助于减轻(不久)将来由生理或社会因素引起的人类生育问题。虽然这项技术仍处于起步阶段,但最近从小鼠多能干细胞中产生的scd配子的进展使一些研究人员和投资者期待在20年内将从诱导多能干细胞(ipscd配子)中提取的人类配子引入临床。然而,这些期望有多现实,以及它们如何与技术、伦理、法律和社会方面的仔细考虑相平衡,包括但不限于安全性和有效性,仍有待研究。这篇小型综述旨在通过提供最新技术的简要概述和强调潜在临床引入人类ipscd配子所涉及的问题的广度,来鼓励这项研究。这些问题出现在临床试验之前(第一阶段)、期间(第二阶段)和之后(第三阶段),并按此顺序进行讨论。在第一阶段的背景下讨论的问题表明,收集临床前评估人类ipscd配子安全性所需的证据将是耗时的,并且需要用敏感的研究材料进行平行实验。在第二阶段的背景下讨论的问题表明,人类ipscd配子可能需要几年的时间才能通过不同的临床试验阶段,并且人类ipscd配子质量的不可避免的(和不可预见的)变化可能会进一步减缓这一过程。最后,在第三阶段背景下讨论的问题表明,临床提供人类ipscd配子将需要解决问责制和监测问题,其中一些问题可能难以通过法律正式确定。总之,这些发现表明,负责任的人类ipscd配子的临床引入可能比预期的要长得多,这强调了与广泛的利益相关者进行跨学科合作的重要性,以便对其开发和应用做出充分了解和深思熟虑的选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Stem cell-derived gametes: what to expect when expecting their clinical introduction.
Stem cell-derived (SCD)-gametes derived from induced or autologous (i.e. patient-specific) cells may help mitigate human fertility problems caused by physiological or social factors in the (near) future. While this technology is still in its infancy, recent advancements with SCD-gametes generated from mouse pluripotent stem cells have led some researchers to expect-and investors to anticipate-the clinical introduction of human gametes derived from induced pluripotent stem cells (iPSCD-gametes) within two decades. However, it remains to be investigated how realistic these expectations are, and how they would balance against careful consideration of technical, ethical, legal, and societal aspects, including-but not limited to-safety and effectiveness. This mini-review aims to encourage that investigation by providing a brief overview of the state-of-the-art and highlighting the breadth of issues involved in the potential clinical introduction of human iPSCD-gametes. These issues emerge before (Stage 1), during (Stage 2), and after (Stage 3) clinical trials, and are discussed in that order. Issues discussed in the context of Stage 1 suggest that gathering the evidence required to preclinically assess the safety of human iPSCD-gametes will be time-consuming and require parallel experiments with sensitive research materials. Issues discussed in the context of Stage 2 suggest that it might take several years for human iPSCD-gametes to transition through distinct clinical trial phases, and that inevitable (and unforeseeable) variations in the quality of human iPSCD-gametes are likely to further slow this down. Finally, issues discussed in the context of Stage 3 suggest that offering human iPSCD-gametes clinically will require addressing questions of accountability and monitoring, some of which might be difficult to formalize by law. Combined, these findings suggest that a responsible clinical introduction of human iPSCD-gametes may take considerably longer than expected, underscoring the importance of transdisciplinary collaborations with a broad range of stakeholders to make well-informed and well-considered choices about their development and application.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Human reproduction
Human reproduction 医学-妇产科学
CiteScore
10.90
自引率
6.60%
发文量
1369
审稿时长
1 months
期刊介绍: Human Reproduction features full-length, peer-reviewed papers reporting original research, concise clinical case reports, as well as opinions and debates on topical issues. Papers published cover the clinical science and medical aspects of reproductive physiology, pathology and endocrinology; including andrology, gonad function, gametogenesis, fertilization, embryo development, implantation, early pregnancy, genetics, genetic diagnosis, oncology, infectious disease, surgery, contraception, infertility treatment, psychology, ethics and social issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信